HIV-associated Lipodystrophy - Epidemiology Forecast to 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 50
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "HIV-associated Lipodystrophy - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the HIV-associated Lipodystrophy epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2028

HIV-associated Lipodystrophy Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for HIV-associated Lipodystrophy in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the HIV-associated Lipodystrophy outlook. It also includes the explanation of changing trends of epidemiology outlining the HIV-associated Lipodystrophy scenario.

HIV-associated Lipodystrophy Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the HIV-associated Lipodystrophy thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

- The report covers detailed overview of HIV-associated Lipodystrophy explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

- It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

- The HIV-associated Lipodystrophy Report assesses the disease risk and burden and highlights the unmet needs

- It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

- 10 Year Forecast

- 7MM Coverage

- Total Cases in HIV-associated Lipodystrophy

Key assessments

- Patient Segmentation in HIV-associated Lipodystrophy

- HIV-associated Lipodystrophy Risk & Burden

- Factors driving growth in a specific HIV-associated Lipodystrophy patient population

HIV-associated Lipodystrophy - Epidemiology Forecast to 2028

Table of Contents

1. Report Introduction
2. HIV-associated Lipodystrophy Epidemiology Overview at a Glance
2.1. Patient Share Distribution of HIV-associated Lipodystrophy in 2016
2.2. Patient Share Distribution of HIV-associated Lipodystrophy in 2028
3. Disease Background and Overview: HIV-associated Lipodystrophy
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of HIV-associated Lipodystrophy in 7MM
4.3. Total Prevalent/ Incident Patient Population of HIV-associated Lipodystrophy in 7MM - By Countries
5. Epidemiology of HIV-associated Lipodystrophy by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.1.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy *
5.1.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.1.5. Diagnosed Cases of the HIV-associated Lipodystrophy
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.4.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy*
5.4.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.4.5. Diagnosed Cases of the HIV-associated Lipodystrophy
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.5.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy*
5.5.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.5.5. Diagnosed Cases of the HIV-associated Lipodystrophy
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.6.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy*
5.6.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.6.5. Diagnosed Cases of the HIV-associated Lipodystrophy
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.7.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy*
5.7.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.7.5. Diagnosed Cases of the HIV-associated Lipodystrophy
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.8.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy*
5.8.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.8.5. Diagnosed Cases of the HIV-associated Lipodystrophy
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.9.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy*
5.9.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.9.5. Diagnosed Cases of the HIV-associated Lipodystrophy
6. Unmet Needs of the HIV-associated Lipodystrophy
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the HIV-associated Lipodystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the HIV-associated Lipodystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the HIV-associated Lipodystrophy in United States (2016-2028)*
Table 5: Sex- Specific Cases of the HIV-associated Lipodystrophy in United States (2016-2028)*
Table 6: Diagnosed Cases of the HIV-associated Lipodystrophy in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the HIV-associated Lipodystrophy in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the HIV-associated Lipodystrophy in Germany (2016-2028) *
Table 10: Diagnosed Cases of the HIV-associated Lipodystrophy in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in France (2016-2028)
Table 12: Sub-Type Specific cases of the HIV-associated Lipodystrophy in France (2016-2028) *
Table 13: Sex- Specific Cases of the HIV-associated Lipodystrophy in France (2016-2028) *
Table 14: Diagnosed Cases of the HIV-associated Lipodystrophy in France (2016-2028)
Table 15: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the HIV-associated Lipodystrophy in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the HIV-associated Lipodystrophy in Italy (2016-2028) *
Table 18: Diagnosed Cases of the HIV-associated Lipodystrophy in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the HIV-associated Lipodystrophy in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the HIV-associated Lipodystrophy in Spain (2016-2028) *
Table 22: Diagnosed Cases of the HIV-associated Lipodystrophy in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in UK (2016-2028)
Table 24: Sub-Type Specific cases of the HIV-associated Lipodystrophy in UK (2016-2028) *
Table 25: Sex- Specific Cases of the HIV-associated Lipodystrophy in UK (2016-2028) *
Table 26: Diagnosed Cases of the HIV-associated Lipodystrophy in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the HIV-associated Lipodystrophy in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the HIV-associated Lipodystrophy in Japan (2016-2028) *
Table 30: Diagnosed Cases of the HIV-associated Lipodystrophy in Japan (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the HIV-associated Lipodystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the HIV-associated Lipodystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the HIV-associated Lipodystrophy in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the HIV-associated Lipodystrophy in United States (2016-2028)*
Figure 6: Diagnosed Cases of the HIV-associated Lipodystrophy in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the HIV-associated Lipodystrophy in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the HIV-associated Lipodystrophy in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the HIV-associated Lipodystrophy in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in France (2016-2028)
Figure 12: Sub-Type Specific cases of the HIV-associated Lipodystrophy in France (2016-2028) *
Figure 13: Sex- Specific Cases of the HIV-associated Lipodystrophy in France (2016-2028) *
Figure 14: Diagnosed Cases of the HIV-associated Lipodystrophy in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the HIV-associated Lipodystrophy in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the HIV-associated Lipodystrophy in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the HIV-associated Lipodystrophy in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the HIV-associated Lipodystrophy in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the HIV-associated Lipodystrophy in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the HIV-associated Lipodystrophy in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the HIV-associated Lipodystrophy in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the HIV-associated Lipodystrophy in UK (2016-2028) *
Figure 26: Diagnosed Cases of the HIV-associated Lipodystrophy in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the HIV-associated Lipodystrophy in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the HIV-associated Lipodystrophy in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the HIV-associated Lipodystrophy in Japan (2016-2028)

  • Antiretroviral Therapy Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 04-Apr-2020        Price: US 3000 Onwards        Pages: 143
    Antiretroviral Therapy Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Antiretroviral Therapy industry with a focus on the Chinese market. The report provides key statistics on the market status of the Antiretroviral Therapy manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-2024 global and Chine......
  • Global Antiretroviral Therapy Market Research Report 2020
    Published: 02-Mar-2020        Price: US 2900 Onwards        Pages: 90
    This report focuses on Antiretroviral Therapy volume and value at global level, regional level and company level. From a global perspective, this report represents overall Antiretroviral Therapy market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan. At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer c......
  • 2020-2025 Global and Regional Antiretroviral Therapy Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report
    Published: 05-Feb-2020        Price: US 3500 Onwards        Pages: 142
    HNY Research projects that the Antiretroviral Therapy market size will grow from XXX in 2019 to XXX by 2025, at an estimated CAGR of XX. The base year considered for the study is 2019, and the market size is projected from 2020 to 2025. By Market Players: By Application Hospital, Clinic, Other By Type NNRTIs, NRTI, Multiclass Combination Products, Integrase Inhibitors By Gilead F. Hoffmann-La Roche, ViiV Healthcare,......
  • Global (United States, European Union and China) Antiretroviral Therapy Market Research Report 2019-2025
    Published: 15-Apr-2019        Price: US 3280 Onwards        Pages: 110
    In 2019, the market size of Antiretroviral Therapy is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Antiretroviral Therapy. This report studies the global market ......
  • Global Antiretroviral Therapy Market Insights, Forecast to 2025
    Published: 06-Feb-2019        Price: US 4900 Onwards        Pages: 113
    The global Antiretroviral Therapy market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Antiretroviral Therapy market based on company, product type, end user and key regions. This report studies the global market size of Antiretroviral Therapy in key regions like North America, Europe, Asia Pacific, Central & South America and Mi......
  • HIV-associated Lipodystrophy - Epidemiology Forecast to 2028
    Published: 15-Jan-2019        Price: US 3250 Onwards        Pages: 50
    DelveInsight's "HIV-associated Lipodystrophy - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the HIV-associated Lipodystrophy epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028. Markets Covered - United States - EU5 (Germany, France, Italy, Spain, and the United Kingdom) - Japan Study Period: 2016-2028 HIV-associated Lipodystrophy Epidemiology......
  • HIV-associated Lipodystrophy - Market Insight, Epidemiology and Market Forecast - 2028
    Published: 15-Jan-2019        Price: US 6250 Onwards        Pages: 100
    DelveInsight's "HIV-associated Lipodystrophy - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the HIV-associated Lipodystrophy epidemiology and market outlook for the 7MM. Markets Covered - United States - EU5 (Germany, France, Italy, Spain, and the United Kingdom) - Japan Study Period: 2016-2028 HIV-associated Lipodystrophy Understanding and Treatment Algorithm The market re......
  • Global and Chinese Antiretroviral Therapy Industry, 2018 Market Research Report
    Published: 22-Nov-2018        Price: US 3000 Onwards        Pages: 137
    The 'Global and Chinese Antiretroviral Therapy Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Antiretroviral Therapy industry with a focus on the Chinese market. The report provides key statistics on the market status of the Antiretroviral Therapy manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industr......
  • Diagnostics and Therapeutics for HIV: Global Markets
    Published: 24-Oct-2018        Price: US 5500 Onwards        Pages: 184
    Report Scope: This report organizes information from diverse sources into sections, including an overview, industry structure, diagnostic test type, treatment by drug categories, leading drug profiles and historic drug sales, regulations, reimbursements and patents. The scope of this report includes an overview of the global market scenario for diagnosis and treatments of HIV, with base year data from 2017, estimations for 2018 and forecasts for 2023 using projections of CAGR duri......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs